Author:
Angyal Adrienn,Longet Stephanie,Moore Shona,Payne Rebecca P.,Harding Adam,Tipton Tom,Rongkard Patpong,Ali Mohammad,Hering Luisa M.,Meardon Naomi,Austin James,Brown Rebecca,Skelly Donal,Gillson Natalie,Dobson Sue L.,Cross Andrew,Sandhar Gurjinder,Kilby Jonathan A.,Tyerman Jessica K.,Nicols Alexander R.,Spegarova Jarmila S.,Mehta Hema,Hornsby Hailey,Whitham Rachel,Conlon Christopher P.,Jeffery Katie,Goulder Philip,Frater John,Dold Christina,Pace Matthew,Ogbe Ane,Brown Helen,Ansari Azim M.,Adland Emily,Brown Anthony,Chand Meera A.,Shields Adrian,Matthews Philippa,Hopkins Susan,Hall Victoria Jane,James William,Rowland-Jones Sarah L.,Klenerman Paul,Dunachie Susanna,Richter Alex G.,Duncan Christopher J. A.,Barnes Eleanor,Carroll Miles W.,Turtle Lance,de Silva Thushan I.,Consortium PITCH
Reference26 articles.
1. MERS-CoV, seasonal human coronaviruses and SARS-CoV-2 486 variants of concern. (A) Comparison of SARS-CoV-1 and MERS-CoV anti-spike antibody 487 responses;SARS-CoV-1
2. -dose, 489 n=21). (B) Comparison of antibody responses to spike proteins from seasonal human 490 coronaviruses 229E, NL63, HKU1 and OC43 before and after vaccination. (C) Surrogate 491 neutralisation activity before and after one vaccine dose in na�ve (n=10) and previously-infected 492 (Prev Inf, n=10) individuals to spike proteins from SARS-CoV-2 variants of concern. Activity 493 estimated by measuring the presence of antibodies able to block the binding of angiotensin-494 converting enzyme 2 (ACE-2) to SARS-CoV-2 spike proteins from D614G, B.1.1.7, B.1.351 and 495 P.1, and expressed as antibody units (AU/ml) (D) Ability of plasma from naive (n=10) and 496 previously-infected individuals (n=10), before and after a single vaccine dose;AU/ml) in na�ve (n=100) and previously infected individuals 488 (Prev Inf, n=110) following a single dose, along with na�ve individuals following two doses
3. Covid-19 Vaccine;New England Journal of Medicine,2020